Mayer Brown advised SERB Pharmaceuticals on the structuring of the acquisition of the US rights to bentracimab, a ticagrelor reversal agent, from SFJ Pharmaceuticals

Paris – Mayer Brown advised the SERB group, a global specialty pharmaceutical group, on the structuring of the acquisition of the exclusive US rights to bentracimab, a ticagrelor reversal agent, from SFJ Pharmaceuticals, a global drug development company. 

Mayer Brown advised SERB Pharmaceuticals on the structuring of the acquisition with a team composed of Partner Olivier Parawan, Associates Sarah Rahmoun and Julia Videau in Paris and Partner Remmelt Reigersman in San Francisco.